Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 9

recruiting
3 968
countries
28
conditions
2 103

103 trials match your criteria

Marginal zone lymphoma+1

Not recruiting

Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide

Follicle centre lymphoma follicular grade I, II - III

Not recruiting

Study Comparing Tisagenlecleucel with Standard Treatment for Adults with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide

Plasma cell myeloma

Not recruiting

Study on Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Lenalidomide, and Dexamethasone for Elderly Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Bortezomib

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Bortezomib, Dexamethasone, Isatuximab, and Iberdomide for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Bortezomib

Plasma cell myeloma

Not recruiting

Study on the Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone in Treating Newly Diagnosed Multiple Myeloma in Patients Eligible for Transplant

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Ixazomib

Plasma cell myeloma

Not recruiting

Study on the Effectiveness of Bortezomib, Melphalan, and Prednisone vs. Carfilzomib, Lenalidomide, and Dexamethasone in Older Adults with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Bortezomib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.